TAIHO PHARMA

SCROLL

We would like to express our deepest sympathies to all those affected by the 2026 Kumamoto Earthquake.

We are driven by the passion to nurture and preserve the precious moments of everyday life for all people, regardless of their health condition. From treatment to disease prevention, we will continue to develop innovative new drugs that contribute to better health and bring smiles to the faces of people everywhere.

August 03, 2026

News Releases

Fujifilm and Taiho Pharmaceutical Enter into Strategic Partnership for Development of Next-Generation Antibody-Drug Conjugate (ADC) Manufacturing Technologies　Optimizing Manufacturing Processes to Enable Stable Production of High-Quality ADCs
July 15, 2026

News Releases

Taiho Pharmaceutical Announces the Launch of PI3Kα Inhibitor HAIZEXIN_® Tablets 10mg in Japan
July 02, 2026

News Releases

Taiho Innovations Begins Operations Under New Organizational Structure　Establishing an Early Clinical Development Function to Strengthen Its Co-Creation Platform
June 25, 2026

News Releases

Taiho Pharmaceutical Earns First Silver Medal in EcoVadis Sustainability Rating
May 14, 2026

News Releases

U.S. FDA Approves INQOVI^® in Combination with Venetoclax, the First All-Oral Combination Treatment for Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction Chemotherapy

MOVIE

TAIHO PHARMA STORY

Introducing Taiho Pharmaceutical’s history and its unique approaches in R&D.